The objective of this study was to determine whether patients beginning therapy on the most common tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) differed in their likelihood of having antidepressant treatment that was consistent with recommended treatment guidelines in the UK. An analytical file constructed from a large general practitioner medical records database (DIN-LINK) from the UK for the years 1992-97 was constructed. A total of 16 204 patients with a new episode of antidepressant therapy who initiated therapy on one of the most often prescribed TCAs (amitriptyline, dothiepin, imipramine and lofepramine) or SSRIs (fluoxetine, paroxetine and sertraline) were analysed. A dichotomous measure was defined to indicate whether subjects were prescribed at least 120 days of antidepressant therapy at an adequate average daily dose within the first 6 months after initiation of therapy. Only 6.0% of patients initiating therapy on aTCA and 32.9% of patients initiating therapy on a SSRI were prescribed antidepressant treatment that was consistent with treatment guidelines. After controlling for observable characteristics, patients who initiated therapy on a SSRI were much more likely (odds ratio=7.473, p<0.001) to have a prescribed average daily dose and duration consistent with recommended treatment guidelines within the first 6 months of initiating therapy than were patients who initiated therapy on a TCA. These findings suggest that initial antidepressant selection is an important determinant of whether the subsequent course of treatment is consistent with current national guidelines for the treatment of depression in the UK.
Introduction
Antidepressant dose and duration are two important factors in achieving the goals of depression treatment which include not only symptom resolution, but also restoration of patients' functioning and prevention of relapse or recurrent episodes. Consensus guidelines have been issued by the British Association for Psychopharmacology (British Association for Psychopharmacology, 1993) and the Royal College of Psychiatrists (Royal College of Psychiatrists, 1992) for the management of depression with antidepressants. For treatment to be effective, they recommend that antidepressants should be prescribed at a dose shown by clinical trials to be effective in treating depression, and continued for at least 4 months beyond initial symptom resolution. These guidelines are broadly consistent with other consensus groups' recommendations (World Health Organization Mental Health Collaborating Centres, 1989 ; Agency for Health Care Policy Research, 1993) .
Most clinical trials of different antidepressants generally show equal efficacy (Effective Health Care Bulletin, 1993; Anderson and Thomenson, 1994; Song et al., 1994) . However, studies of antidepressant use in clinical practice ('naturalistic' studies) have shown that most patients who initiate therapy on a tricyclic antidepressant (TCA) in primary care in the UK begin at suboptimal doses and remain there (Donoghue and Tylee, 1996; Martin et al., 1997) . In addition, studies have also shown that most patients beginning treatment with a TCA are less likely than patients on selective serotonin reuptake inhibitors (SSRIs) to refill their prescriptions and often discontinue therapy by the third month (MacDonald, 1997) .
Naturalistic, observational studies of antidepressant use in clinical practice can complement the findings from controlled trials. A feature of observational studies is that the results are more generalizable to broader populations than those considered in controlled clinical trials due to the lack of study conditions or protocol restrictions. However, unlike randomized controlled clinical trials, observational studies are subject to the influence of confounding factors. Previous observational studies of antidepressant prescribing patterns in primary care in the UK have been limited by their cross-sectional design (Donoghue, 1995 (Donoghue, , 1996 . In addition, the only naturalistic, longitudinal study of antidepressant prescribing patterns in the UK to date did not address the influence of other observed patient or prescriber characteristics on prescribing patterns (MacDonald, 1997) . Thus, it was unclear whether the differences in observed prescribing patterns were due to the drugs or to other factors that influence both drug selection and prescribing.
The purpose of this study was to assess how the prescribing patterns of different antidepressants in the first 6 months following initiation of treatment compare with recommended depression treatment guidelines in the UK. We considered a sample of patients in primary care who had a depressionrelated diagnosis at the initiation of therapy. All patients in this study initiated therapy on one of the most commonly prescribed TCAs (amitriptyline, dothiepin, imipramine and lofepramine) or SSRIs (fluoxetine, paroxetine and sertraline), which represented over 97% of all antidepressant prescribing in primary care in this study. Unlike earlier studies, this one considers a longer period of prescribing data (1992-97), constructs and analyses patients' episodes of antidepressant use, and uses logistic regression analysis to control for the influence of other observed factors.
Methods

Data
The analysis file used in this study was constructed from the 1992-97 panels of the Doctors' Independent Network (DIN-LINK), which is maintained by CompuFile Ltd. (Woking, UK). DIN-LINK is a system of comprehensive and standardized medical and prescription records for approximately 750 000 patients from 100 general practices in the UK that use AAH Meditel practice software. A 6-month antidepressantfree period prior to the index date was used to ensure that antidepressant prescribing was not part of an earlier episode. Episodes of antidepressant therapy were then constructed using an intent-to-treat basis. In an intent-to-treat design, patients' subsequent experience in the study period is attributed back to the original TCA or SSRI selected, regardless of subsequent use. For example, if a patient begins on a TCA and then switches to a SSRI or another antidepressant, the patient remains in the TCA category for the analysis. An intent-to-treat analysis is consistent with examining the consequences of initial antidepressant selection (Simon et al., 1996) .
The 'index study' antidepressant was one of the four study TCAs or three SSRIs on which the patient began therapy. The index date was defined as the date on which the first prescription for the study antidepressant was issued and was accompanied by one of five depression-related diagnoses (as recorded in the medical record, including endogenous depression, reactive depression, depressed, on examination depressed or depression not otherwise specified) within a 30-day period around the index date. These diagnoses are consistent with those used and validated in earlier analyses of the DIN-LINK data (Donoghue, 1996; . General practitioners use all of these terms to describe depression in primary care in the UK, and do not use them consistently to differentiate between different manifestations of depression.
Patients were excluded if they: (I) were unable to be followed for at least 180 days before the index date; (2) (Simon et al., 1993; Fairman, 1997 depressed, with depression not otherwise specified as the reference group). Second., binary indicator variables were created for the following conditions if they occurred in the 180-day period prior to initiation of therapy: cancer, chronic fatigue syndrome, coronary artery disease, stroke, diabetes and fibromyalgia. These are conditions commonly coexisting with depression (AHCPR, 1993) . Third, several variables were created which represented counts of the following occurrences in the 180-day prior period: anxiolytic prescriptions, sedative-hypnotics prescriptions, general practitioner visits, general practitioner referrals, psychotherapy referrals, laboratory referrals, psychiatric accident and emergency admissions, psychiatric non-accident and emergency admissions, general accident and emergency admissions and general non-accident and emergency admissions. Fourth, in an attempt to control for concomitant psychiatric conditions, indicators were created for Psychiatric Diagnostic Groups (Ashcraft et al., 1989) which are based on the ICD-9 classification scheme. Psychiatric Diagnostic Groups were defined as a method of classifying major psychiatric conditions and are therefore analogous to the Major Diagnostic Categories used in the Diagnosis Related Groups classification system.
Finally, an additional variable was included to reduce the effect of factors related to the general practice characteristics such as habitual antidepressant prescribing practices. This variable represents the probability that the general practitioners at the patient's general practice prescribed SSRIs and was measured by computing the percentage of the general practice's study antidepressant prescriptions which were for SSRIs during the study period. Physicians' practice patterns may be shaped by a number of influences, including previous experience with the product and the information physicians receive about the product and its use. Thus, unlike previous studies of antidepressant prescribing, it was possible to control for underlying differences in general practices that are likely to prescribe TCAs or SSRIs. In this way, differences in physicians' habitual prescribing practices, preferences or previous experiences with different classes of drugs are controlled for (Simon and Fishman, 1998) .
A standard significance level (p<0.05) was used for the analysis. The SAS package (SAS Institute, Cary, North Carolina, USA) was used to construct the dataset and perform the logistic regression analysis. (Henry et al., 1995) . Recent analyses have also found a perception among general practitioners of differences in tolerability between the TCAs and SSRIs (Martin et al., 1997) . In addition, it is acknowledged that lofepramine does appear to be used differently in clinical practice owing to (at least perceived) differences in tolerability . Thus, there is some evidence that antidepressant prescribing in clinical practice may be driven, in part, by the perception of tolerability differences across TCAs and SSRIs.
Results
In this study, overall rates of prescribing of TCA and SSRI antidepressants in relation to treatment guidelines were low. 00 10024 However, patients who initiated therapy on a SSRI had an odds ratio over sevenfold higher than patients who initiated therapy on a TCA of having an adequate daily dose and duration of antidepressant therapy consistent with recommended treatment guidelines. In light of the absolute differences between the classes of antidepressants (6% for TCA patients and 32.9% for SSRI patients), this difference is also clinically relevant, particularly when it is considered over a large population. The large sample size and the similarity of findings of previous studies of antidepressant prescribing using these data with other databases in the UK contributes to the generalizability of these data to the UK as a whole. Consistent with earlier cross-sectional studies Martin et al., 1997) , patients who initiated therapy on SSRIs were more likely to achieve recommended therapeutic doses than their counterparts on TCAs in primary care in the UK. The results were also qualitatively consistent with the earlier longitudinal study in Scotland (MacDonald, 1997 (Simon et al., 1996) . While that finding contrasts with the results of this study, it may be that the physicians who participated in that trial are systematically different than the typical physicians observed in clinical practice in terms of their experience in participating in trials and how they manage patients on antidepressants. Patients referred to that trial may also have been systematically different than patients in the general population. This possibility is consistent with the finding of a similar retrospective (non-clinical trial) study of a broader sample of physicians and patients in the Group Health Cooperative setting which found that the likelihood of continuing antidepressant on any medication was statistically significantly higher for patients who had initiated therapy on the SSRI fluoxetine than patients who had initiated therapy on a TCA (Katon et al., 1992) .
The relatively low rates of adequate daily dose and duration for patients initiating therapy on any antidepressant are striking in light of the recent Defeat Depression campaign in the period 1991-96 in the UK (Priest, 1994) . For the 1992-94 period of the sample, 5.3% of TCA patients had an adequate dose and duration of therapy vs 7.9% of TCA patients in 1995-97, while the figures for SSRI subjects were 29.4% in 1992-94 and 37.8% in 1995-97. An earlier cross-sectional analysis of prescriptions in the DIN-LINK data found that the rate of adequate dose of antidepressant prescribing had increased during 1993-95, due largely to increased prescribing of the SSRIs (Donoghue et at., 1996) . It would appear that efforts to increase awareness of appropriate treatment strategies with antidepressants have increased the likelihood of achieving adequate daily dose and duration, regardless of which antidepressant they were prescribed. Even in light of this educational awareness program, it would appear that this likelihood is still greater with an SSRI relative to a TCA.
The observed prescribing patterns of TCAs and SSRIs in clinical practice may also have implications for cost-effectiveness comparisons that rely upon controlled clinical trial data. Recent analyses have concluded that because TCAs and SSRIs are generally equally efficacious, TCAs represent a more costeffective solution because of the acquisition price differential (Effective Health Care Bulletin, 1993; Song et al., 1994; Hotopf et at., 1996) . This conclusion might have credence if TCAs were used in actual clinical practice in the same way they are used in clinical trials (i.e. at adequate doses for sufficient duration). However, the findings of this and other studies indicate they are not. Rather, patients on TCAs begin at low doses and remain there. This study's results were found despite the fact that the study design included aspects that favoured the TCAs. First, using an intent-to-treat design allows the results from patients who switched antidepressant class to be attributed to the patient's initial drug class. This favours TCAs because more patients who initiated therapy on TCAs switched to SSRIs than vice versa, and SSRI patients were more likely to achieve adequate daily dose and duration. Second, including lofepramine in the TCA category leads to a higher rate of TCA patients achieving an adequate dose and duration. While lofepramine is a TCA. it is generally thought to have lower toxicity, and thus may be better tolerated, and was found to have a different pattern of prescribing relative to ainitriptyline and dothiepin . The lower odds ratio for SSRI patients relative to lofepramine patients may only reflect the greater similarity in the use of SSRIs and lofepramine.
Despite the recommended treatment guidelines in the UK, some have recently argued that lower doses of TCAs are appropriate (Benkert et al., 1996; Moore, 1997; Tan, 1997 (Farmer, 1997) .
Given the non-randomization into initial antidepressant, it is possible that differences in antidepressant prescribing patterns among patients initiating therapy on one of the antidepressants were the result of unobserved differences across patients or general practitioners that were not controlled for in the analysis. For example, it might be that some patients on the SSRIs differed from TCA patients in underlying severity, which was not captured by the observed variables. However, given the information available in this database and the study design and methods applied, the bias due to unobserved factors is unlikely to be large. For example, to control for baseline patient differences, a 6-month prior period, an extensive set of observable baseline characteristics, and measures of general practices' experience with the study antidepressants were used to control for as many of the baseline patient and physician characteristics as possible. In addition, comorbid disease variables were included to control for observed differences across the patient groups in disease severity. Thus, the observed difference between drug classes is statistically significant even after controlling for these other observed factors.
A recent study (Simon and Fishman, 1998) also found that physicians' habitual prescribing preferences were a stronger determinant of initial antidepressant drug selection than patient characteristics. There is also other evidence indicating that some general practitioners prescribe the same antidepressant for most patients rather than considering specific patient characteristics when selecting the antidepressant (Matthews et al., 1993 (Mintz et al., 1992) while another study found that doubling the rate of adequate daily dose and duration led to a significant reduction in major disabilities (Sturm and Wells, 1995) . An adequate length of stable antidepressant therapy at an effective dose is also an important determinant of the prevention of relapse (Maj et al., 1992) . Additional studies are needed to more directly assess the relationship between treatment consistent with guidelines and clinical outcomes.
It was not possible to identify the reasons for the observed dose and duration of therapy. Potential reasons underlying discontinuation prior to receiving at least 120 days of therapy within the first 6 months may include lack of clinical effect, intolerable adverse events, or spontaneous symptom resolution. It is not possible to determine whether the observed pattern and lengths of therapy were related to clinical symptom resolution or to poor patient or prescriber understanding of the need to continue treatment for a longer period of time. Patients who had shorter prescribing patterns may have been less severely ill and the decision may have been made to discontinue therapy in light of earlier symptom resolution. On the other hand, some of the patients who had less than 120 days within the first 6 months may have been more severely ill but experienced adverse events or lack of efficacy and thus abandoned treatment altogether.
This study has shown differences in the patterns of antidepressant prescribing among the most common antidepressants in primary care in the UK. It would be useful to study the relationships between patterns of antidepressant prescribing, health care expenditures, and clinical outcomes observed within this primary care setting in the UK. Finally, it would be useful to consider whether patterns of antidepressant prescribing differ among the most common SSRIs.
